Operates in the personal care products segment and was listed on BSE in late 2025. FY26 revenue was ₹26.95 crore against total assets of ₹37.63 crore. The company raised capital through an IPO earmarked primarily for a manufacturing facility in Amravati and for marketing, but only a small share of proceeds had been deployed by March 31, 2026. The Amravati plant has not been started, with the allocated capital still parked in bank deposits. The cost structure is dominated by other operating expenses, which run at 47.2% of revenue, with employee costs at 3.8% and reported materials cost at 0%. The company carries no debt, while trade receivables expanded sharply year-on-year. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Personal care products. Recently listed personal care products company; capital-light currently, with planned manufacturing facility not yet set up and zero debt
| ₹ crore · consolidated | FY26 |
|---|---|
| Revenue | 27 |
| EBITDA (ex other income) | — |
| margin % | — |
| Owners' profit | — |
| EPS, as reported (₹) | 9.20 |
| ROE % · ROCE % | — · 18.9 |
| Debt / equity (x) | — |
| Cash from operations | (17) |
| Capex | (2) |
| ₹ crore | Q4 FY26 |
|---|---|
| Revenue | 13 |
| Profit before tax | 3 |
| Net profit | — |
| EPS (₹) | 3.48 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| GODREJ CONSUMER PRODUCTS | 88,507 | 46.2 | 6.99 | 28.7 | 14.7 | 19.0 | 6.6 | 19.8 |
| DABUR INDIA LTD | 66,702 | 33.8 | 5.65 | 22.3 | 15.8 | 19.8 | 6.6 | 24.3 |
| COLGATE PALMOLIVE LTD. | 48,889 | 36.3 | 30.86 | — | 83.7 | 107.1 | — | 31.3 |
| CUPID LIMITED | 37,644 | 102.9 | 83.50 | 249.5 | 24.0 | 30.3 | — | 40.3 |
| P&G HYGIENE & HEALTH CARE | 24,410 | 30.9 | 32.40 | — | 113.7 | 134.4 | — | 20.1 |
| GILLETTE INDIA LTD | 23,807 | 35.6 | 25.15 | — | 69.1 | 83.4 | — | 29.8 |
| EMAMI LIMITED | 15,893 | 21.2 | 5.44 | 15.3 | 26.5 | 28.4 | 5.6 | 23.5 |
| HONASA CONSUMER LIMITED | 15,331 | 52.9 | 10.86 | 48.3 | 14.2 | 16.9 | — | 17.6 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 1 Sept 2026 · 8th AGM Notice Published in Newspapers | compliance | minimal | — | — |
| 31 Aug 2026 · Ravelcare FY26 Annual Report and 8th AGM Notice filed with BSE | board shareholder meetings | medium | — | — |
| 26 Aug 2026 · Ravelcare launches Ravel PRO haircare, AI skincare range in H2 FY27 | business updates | medium | — | — |
| 25 Aug 2026 · Ravelcare: promoter MD and WTD re-appointed for 3 years; office shifted within Mumbai | management changes | high | — | — |
| 25 Aug 2026 · Ravelcare board re-appoints promoter directors, shifts registered office | management changes | high | — | — |
| 25 Aug 2026 · Board approves re-appointment of MD, Whole-time Director; shifts registered office | management changes | medium | — | — |
| 14 Jul 2026 · Certificate under Regulation 74(5) filed for quarter ended June 30, 2026 | compliance | minimal | — | — |
| 30 May 2026 · Statement of utilisation of funds | compliance | minimal | — | — |
| 30 May 2026 · Financial Results | results | high | — | — |
| 30 May 2026 · Outcome of Board Meeting | results | high | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 30.2 | 36.3 | 3 of 15 | 86% |
| ROCE | 18.9 | 19.4 | 10 of 16 | 40% |
| Market cap | 72 | 11078 | 14 of 16 | 13% |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
